TP53 Mutations Promote Immunogenic Activity in Breast Cancer

BACKGROUND: Although immunotherapy has recently achieved clinical successes in a variety of cancers, thus far there is no immunotherapeutic strategy for breast cancer (BC). Thus, it is important to discover biomarkers for identifying BC patients responsive to immunotherapy. TP53 mutations were often...

Täydet tiedot

Tallennettuna:
Bibliografiset tiedot
Julkaisussa:J Oncol
Päätekijät: Liu, Zhixian, Jiang, Zehang, Gao, Yingsheng, Wang, Lirui, Chen, Cai, Wang, Xiaosheng
Aineistotyyppi: Artigo
Kieli:Inglês
Julkaistu: Hindawi 2019
Aiheet:
Research Article
Linkit:https://ncbi.nlm.nih.gov/pmc/articles/PMC6582869/
https://ncbi.nlm.nih.gov/pubmed/31275382
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1155/2019/5952836
Tagit: Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!

Samankaltaisia teoksia